Immunization against severe acute respiratory syndrome Coronavirus 2: an overview
- PMID: 35283984
- PMCID: PMC8889804
- DOI: 10.4314/ahs.v21i4.11
Immunization against severe acute respiratory syndrome Coronavirus 2: an overview
Abstract
In the past years, numerous new fatal infections have emerged, including Ebola, Nipah, and Zika viruses, as well as coronaviruses. Recently, infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged in China, and were then transmitted all over the world, causing the coronavirus disease-19 (COVID-19) pandemic, which is transmitted at a higher rate than other diseases caused by coronaviruses. At the time of writing this review, COVID-19 is not contained in most countries in spite of quarantine, physical distancing, and enhanced hygiene measures. In this review, I address different methods for passive and active immunization against this virus, which is known to cause fatal respiratory disease, including natural passive immunization by breast milk, natural active immunization by herd immunization, artificial passive immunization by convalescent plasma or monoclonal antibodies, and artificial active immunization by vaccination. I hope this review will help design a prophylactic approach against outbreaks and pandemics of related coronaviruses in the future.
Keywords: Breastfeeding; COVID-19; SARS-CoV; herd immunity; monoclonal antibodies; vaccine.
© 2021 El-Masry EA.
Similar articles
-
Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.Acta Microbiol Immunol Hung. 2020 Jul 3;67(2):87-90. doi: 10.1556/030.2020.01199. Acta Microbiol Immunol Hung. 2020. PMID: 32619190
-
Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.Semin Thromb Hemost. 2020 Oct;46(7):796-803. doi: 10.1055/s-0040-1712157. Epub 2020 Jun 11. Semin Thromb Hemost. 2020. PMID: 32526774 Free PMC article. Review.
-
Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.Breastfeed Med. 2021 May;16(5):393-401. doi: 10.1089/bfm.2020.0381. Epub 2021 Apr 9. Breastfeed Med. 2021. PMID: 33835835
-
High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.Transfusion. 2021 May;61(5):1377-1382. doi: 10.1111/trf.16318. Epub 2021 Feb 18. Transfusion. 2021. PMID: 33604922 Free PMC article. Clinical Trial.
-
Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.Blood Purif. 2022;51(1):1-14. doi: 10.1159/000513164. Epub 2021 Mar 31. Blood Purif. 2022. PMID: 33789273 Free PMC article. Review.
Cited by
-
Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses.Pharmaceuticals (Basel). 2022 Apr 24;15(5):521. doi: 10.3390/ph15050521. Pharmaceuticals (Basel). 2022. PMID: 35631348 Free PMC article.
-
Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.Front Immunol. 2022 May 27;13:876533. doi: 10.3389/fimmu.2022.876533. eCollection 2022. Front Immunol. 2022. PMID: 35711413 Free PMC article.
References
-
- Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86(7):3995–4008. doi: 10.1128/JVI.06540-11. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous